These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11414163)

  • 21. [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
    Lamarque D
    Bull Cancer; 2004 May; 91 Spec No():S117-24. PubMed ID: 15239340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
    White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM
    Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
    Lanas A; Baron JA; Sandler RS; Horgan K; Bolognese J; Oxenius B; Quan H; Watson D; Cook TJ; Schoen R; Burke C; Loftus S; Niv Y; Ridell R; Morton D; Bresalier R
    Gastroenterology; 2007 Feb; 132(2):490-7. PubMed ID: 17258718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [COX-2 inhibitors--one step forward and two steps back].
    Evensen S; Spigset O; Slørdal L
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):875-8. PubMed ID: 15815733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreasing incidence of symptomatic gastrointestinal ulcers and ulcer complications in patients with rheumatoid arthritis.
    Steen KS; Nurmohamed MT; Visman I; Heijerman M; Boers M; Dijkmans BA; Lems WF
    Ann Rheum Dis; 2008 Feb; 67(2):256-9. PubMed ID: 17604285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.
    Watson DJ; Yu Q; Bolognese JA; Reicin AS; Simon TJ
    Curr Med Res Opin; 2004 Oct; 20(10):1539-48. PubMed ID: 15462687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
    Zhao SZ; Wentworth C; Burke TA; Makuch RW
    Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors associated with the development of gastroduodenal ulcers due to the use of NSAIDs.
    Wolfe MM
    Int J Clin Pract Suppl; 2003 Apr; (135):32-7. PubMed ID: 12723745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?
    Chen JT; Pucino F; Resman-Targoff BH
    J Pain Palliat Care Pharmacother; 2006; 20(4):11-32. PubMed ID: 17182503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonsteroidal anti-inflammatory drugs in the elderly.
    Buffum M; Buffum JC
    Pain Manag Nurs; 2000 Jun; 1(2):40-50. PubMed ID: 11706458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non-steroidal anti-inflammatory drugs: what are the connections?
    McCarthy DM
    Eur J Surg Suppl; 2002; (587):89-99. PubMed ID: 16144207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
    Goldstein JL; Cryer B; Amer F; Hunt B
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon.
    Fiorucci S; Santucci L; Distrutti E
    Dig Liver Dis; 2007 Dec; 39(12):1043-51. PubMed ID: 17997373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Arthritis. Should you be taking a COX-2 inhibitor?
    Harv Health Lett; 2001 Nov; 27(1):1-3. PubMed ID: 11724695
    [No Abstract]   [Full Text] [Related]  

  • 39. [Gastrointestinal complications caused by NSAIDs. Over 60% of arthrosis patients are endangered].
    MMW Fortschr Med; 2003 Mar; 145(10):60. PubMed ID: 12688036
    [No Abstract]   [Full Text] [Related]  

  • 40. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.